MORAb-004 + gemcitabine + docetaxel

This is a **combination regimen** of three drugs: - **MORAb-004 (ontuxizumab)**: a humanized monoclonal antibody targeting endosialin (also known as TEM-1 or CD248), expressed on activated mesenchymal cells such as tumor-associated pericytes and activated fibroblasts. MORAb-004 disrupts tumor neovascularization and stromal interactions, impairing the growth of several solid tumor types by promoting internalization and reduction of CD248 on pericytes, resulting in impaired initiation and maturation of tumor microvasculature, and subsequent inhibition of angiogenesis and metastasis[1][3][4]. - **Gemcitabine**: a nucleoside analog (antimetabolite) chemotherapeutic that inhibits DNA synthesis and is commonly used in a variety of solid tumors, including pancreatic, lung, and breast cancers. - **Docetaxel**: a taxane class chemotherapeutic agent that promotes microtubule assembly and inhibits depolymerization, disrupting mitosis in cancer cells. This combination has been explored in investigational clinical trials, though to date, no regulatory approvals are noted, and combination-specific efficacy or phase development status with this exact triplet is not definitively established in the literature.

Brand names

ontuxizumab

Other names

MORAb-004 + gemcitabine + docetaxel